Enedra Welcomes Adrian Ibrahim as CEO—Together, We’re Tackling Cancer’s Toughest Challenge

Our little company has grown into one of the most exceptional teams in drug discovery—and we couldn’t be prouder.

From day one, our vision has been clear: to tackle cancer’s toughest challenge—genomic heterogeneity, which drives therapy resistance and accounts for 90% of patient deaths.

At Enedra, we’re taking a different approach: harnessing cancer evolution rather than fighting it. Our AI-driven platform uncovers conserved survival mechanisms across genetically diverse tumour cells, enabling first-in-class targeted therapies designed for potent and durable responses.

We’re now entering the next phase—developing our first lead small molecules.

We’re thrilled to welcome Adrian Ibrahim as CEO. Adrian is a strategic leader with deep expertise in company creation and technology commercialisation, and his 30-year track record speaks for itself. His leadership, combined with the strength of our exceptional team, gives us everything we need to succeed.

Our first programme targets a colorectal cancer segment where no current therapy works for nearly 70,000 patients each year, with multi-indication potential. Together, we’re on track to bring life-saving therapies to patients in the very near future.

Checkmating cancer evolution—join us.
Learn more: enedratx.com